Bizarre Patents
An armor with rollers is provided that enables a user to move in all positions by rolling on a hard and smooth surface while constantly varying his bearing points on the ground.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8153129 | Antibodies against human cytimegalovirus (HCMV) The present invention provides novel antibody sequences that bind human cytomegalovirus (hCMV) and neutralize hCMV infection. The novel sequences can be used for the medical management of hCMV infections, in particular for preparing pharmaceutical compositions to be... | 04/10/2012 |
| 8137671 | Anti-IL-17F antibodies This invention provides fully human monoclonal antibodies that recognize IL-17F and/or the heterodimeric IL-17A/IL-17F complex, but do not recognize IL-17A. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and ... | 03/20/2012 |
| 8128933 | Method of promoting bone growth by an anti-activin B antibody In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density. ... | 03/06/2012 |
| 8097254 | Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis The present invention relates to antibodies with sub-nanomolar affinity specific for a characteristic epitope of the ED-B domain of fibronectin, a marker of angiogenesis. Furthermore, it relates to the use of radiolabelled high affinity anti ED-B antibodies for dete... | 01/17/2012 |
| 7968092 | Human binding molecule against CD1a The present invention provides human binding molecules that specifically bind to CD1a, nucleic acid molecules encoding the human binding molecules, compositions comprising the human binding molecules and methods of identifying or producing the human binding m... | 06/28/2011 |
| 7939075 | Human monoclonal anti-amyloid-beta antibodies Isolated, monoclonal, human, anti-β-amyloid antibodies are provided which bind to dimeric forms of Ab with higher affinity than to monomeric forms of Ab and when bound to an Aβ polypeptide comprising Aβ(21-37) shield Aβ(21-37) from proteolytic digestion. The ant... | 05/10/2011 |
| 7901683 | Methods of inhibiting amyloid toxicity The present invention features methods and compositions for inhibiting amyloidogenic protein toxicity, inhibiting formation of an amyloidogenic protein deposit and/or treating amyloidogenic diseases by administering a pharmaceutically effective amount of one or more... | 03/08/2011 |
| 7887804 | Methods for treating disease-states associated with RG1 using immunoconjugates The present invention relates to novel human extracellular matrix polypeptides, designated RG1, polynucleotides encoding the polypeptides, methods for producing the polypeptides, expression vectors and genetically engineered host cells for expression of the polypept... | 02/15/2011 |
| 7879326 | Human neutralizing monoclonal antibodies to H5N1 influenza A virus A panel of IgG1 human monoclonal antibodies (HMAbs) identified by hemagglutination inhibition (HI) assay has been produced from peripheral B cells of an individual immunized with prototype H5N1 vaccine. Sequence analysis of antibody clones showed three cl... | 02/01/2011 |
| 7829090 | Human antibody molecules for IL-13 Specific binding members, in particular human anti-IL-13 antibody molecules and especially those which neutralise IL-13 activity. Methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, including asthma, atopic dermatiti... | 11/09/2010 |
| 7824679 | Human monoclonal antibodies to CTLA-4 In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucelotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, ... | 11/02/2010 |
| 7763249 | Human anti-amyloid β peptide antibody and fragment of said antibody A human anti-amyloid β peptide (hereinafter referred to as “Aβ”) antibody that binds to Aβ to thereby inhibit aggregation of Aβ molecules, and a fragment of said antibody are provided. The antibody and a fragment thereof according to the present invention, c... | 07/27/2010 |
| 7754213 | High affinity antibody antagonists of interleukin-13 receptor alpha 1 High affinity antibody antagonists of human interleukin-13 receptor alpha 1 are disclosed. The antibody molecules are effective in the inhibition of IL-13Rα1-mediated activities and, accordingly, present desirable antagonists for the use in the treatment of conditi... | 07/13/2010 |
| 7722873 | Heterologous antibodies which bind human CD4 The invention relates to transgenic non-human animals capable of producing high affinity human sequence antibodies. The invention is also directed to human sequence antibodies specific for human antigens, such as, human CD4. The invention also is directed to methods... | 05/25/2010 |
| 7645451 | Human dickkopf-related protein and nucleic acid molecules and uses therefor Novel Dkk and Dkk-related polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length Dkk and Dkk-related proteins, the invention further provides isolated fusion proteins, antigenic peptides and antibodies. The invention a... | 01/12/2010 |
| 7611706 | RG1 antibodies and uses thereof The present invention relates to antibodies, and antigen-binding antibody fragments, directed against an RG1 polypeptide. The invention further relates to methods for utilizing the antibodies, and antibody fragments, for diagnostic and therapeutic applications. ... | 11/03/2009 |
| 7608263 | RG1 antibodies and uses thereof The present invention relates to antibodies, and antigen-binding antibody fragments, directed against an RG1 polypeptide. The invention further relates to methods for utilizing the antibodies, and antibody fragments, for diagnostic and therapeutic applications. ... | 10/27/2009 |
| 7601353 | Peptide-based passive immunization therapy for treatment of atherosclerosis The present invention relates to passive immunization for treating or preventing atherosclerosis using an isolated human antibody directed towards at least one oxidized fragment of apolipoprotein B in the manufacture of a pharmaceutical composition for therapeutical... | 10/13/2009 |
| 7595048 | Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1 Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of the immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods o... | 09/29/2009 |
| 7588761 | Human antibodies that bind human TNFα Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., Kd=10−8 M or less), a slow off rate for hTNFα d... | 09/15/2009 |
| 7585504 | High affinity antibodies against HMGB1 and methods of use thereof Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise, for example, high affinity antibodies that specifical... | 09/08/2009 |
| 7541031 | Methods for treating rheumatoid arthritis using human antibodies that bind human TNFα Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., Kd=10−8 M or less), a slow off rate for hTNFα d... | 06/02/2009 |
| 7521050 | Human antibodies that bind human TNFα Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., Kd=10−8 M or less), a slow off rate for hTNFα d... | 04/21/2009 |
| 7473423 | Human IgM antibodies, and diagnostic and therapeutic uses thereof particularly in the central nervous system Antibodies, and particularly human antibodies, are disclosed that demonstrate activity in the treatment of demyelinating diseases as well as other diseases of the central nervous system that are of viral, bacterial or idiopathic origin, including neural dysfunction ... | 01/06/2009 |
| 7442373 | Antibodies against protective antigen and methods of use for passive immunization and treatment of anthrax A highly efficient method for generating human antibodies using recall technology is provided. In one aspect, human antibodies which are specific to the anthrax toxin are provided. In one aspect, human peripheral blood cells that have been pre-exposed to anthrax tox... | 10/28/2008 |
| 7438909 | Immunization and treatment methods for anthrax A highly efficient method for generating human antibodies using recall technology is provided. In one aspect, human antibodies which are specific to the anthrax toxin are provided. In one aspect, human peripheral blood cells that have been pre-exposed to anthrax tox... | 10/21/2008 |
| 7438905 | Methods of suppressing, treating, or preventing graft rejection with an antibody or a portion thereof that binds to AILIM Graft rejection is a serious problem associated with tissue or organ transplantation (e.g., allotransplantation or xenotransplantation), performed to treat various organ failures (e.g., liver, heart, lung, kidney, or pancreas). Described are pharmaceutical compositi... | 10/21/2008 |
| 7435415 | Monoclonal antibodies and cell surface antigens for the detection and treatment of small cell lung cancer (SCLC) The invention provides new monoclonal antibodies and binding fragments thereof which recognize and immunoreact with cell surface antigens found on small cell lung cancer (SCLC) cells. The antibodies have tumor specificity and are useful for therapy, diagnosis, monit... | 10/14/2008 |
| 7432359 | Anti-A33 antibody The present invention provides: an antibody or a antibody fragment thereof, which can bind to A33, which specifically attacks A33-expressing tumor cells with the use of ADCC and CDC based on the immune system, and for which no HAHA is produced; and a preventive or t... | 10/07/2008 |
| 7429646 | Antibodies to human tumor necrosis factor receptor-like 2 The present invention relates to novel members of the Tumor Necrosis Factor family of receptors. The invention provides isolated nucleic acid molecules encoding a human TR2 receptor and two splice variants thereof. TR2 polypeptides are also provided as are vectors, ... | 09/30/2008 |
| 7429379 | TNF receptor action modulation A method of modulating signal transduction and/or cleavage in Tumor Necrosis Factor Receptors (TNF-Rs) is provided. Peptides or other molecules may interact either with the receptor itself, or with effector proteins interacting with the receptor, thus modulating the... | 09/30/2008 |
| 7429380 | Production of a multimeric protein by cell fusion method The present invention features a method of producing a multimeric protein from a hybrid cell formed from the fusion of two or more cells, each of which cell is engineered to express one component of the multimeric protein, as well as a method for screening for succe... | 09/30/2008 |
| 7427399 | Antibodies and related molecules that bind to 161P2F10B proteins Antibodies and molecules derived therefrom that bind to 161P2F10B protein and variants thereof, are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 16... | 09/23/2008 |
| 7425619 | FcγRIIB specific antibodies and methods of use thereof The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA. The invention provides methods ... | 09/16/2008 |
| 7416727 | Polypeptide variants with altered effector function The present invention concerns polypeptides comprising a variant Fc region. More particularly, the present invention concerns Fc region-containing polypeptides that have altered effector function as a consequence of one or more amino acid modifications in the Fc reg... | 08/26/2008 |
| 7413737 | Anti-hydroxylase antibodies and uses thereof Antibodies, or antigen-binding portions thereof, to aspartyl (asparaginyl) β-hydroxylase are provided. The anti-aspartyl (asparaginyl) β-hydroxylase antibodies, or antigen-binding portions thereof, can modulate activity of aspartyl (asparaginyl) β-hydroxylase. | 08/19/2008 |
| 7390491 | Agents comprising midkine or an inhibitor thereof as active ingredient Midkine (MK), which is a retinoic acid-inducible heparin-binding growth factor, enhances neutrophilic migration and exists in an inflammatory state at a high concentration. The midkine or its inhibitors can be used for treating neutrophilic functional disorders or i... | 06/24/2008 |
| 7387772 | Chimeric, human and humanized anti-CSAP monoclonal antibodies The present invention provides humanized, chimeric and human anti-CSAp antibodies and anti-CSAp antibody fusion proteins that are useful for the treatment and diagnosis of various cancers, including colon cancer. ... | 06/17/2008 |
| 7384633 | Human type antihuman IgE receptor antibody and fragment An antibody or an antibody fragment is provided that is efficacious for treating allergic diseases in which IgE is involved. A human antibody and a fragment thereof to a receptor (FcεRI) having high affinity to Fc portion of IgE was obtained using phage antibody di... | 06/10/2008 |
| 7384632 | Agonist anti-trk-C monoclonal antibodies The invention concerns agonist anti-trkC monoclonal antoibodies which mimic certain biological activities of NT-3, the native ligand of trkC. The invention further concerns the use of such antibodies in the prevention and/or treatment of cellular degeneration, inclu... | 06/10/2008 |
